<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                          August 20, 2024

John Caplan
Chief Executive Officer and Director
Payoneer Global Inc.
195 Broadway, 27th Floor
New York, New York 10007

       Re: Payoneer Global Inc.
           Schedule TO-I and Schedule 13E-3 filed August 12, 2024
           File No. 005-92642
Dear John Caplan:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

        Please respond to these comments by providing the requested information
or advise us as
soon as possible when you will respond. If you do not believe our comments
apply to your facts
and circumstances, please tell us why in your response.

       After reviewing your response to these comments, we may have additional
comments.

Schedule TO-I and Schedule 13E-3 filed August 12, 2024
General

1.     Where a filing person elects to incorporate by reference the information
required by Item
       1010(a) of Regulation M-A, all of the summarized financial information
required by Item
       1010(c) must be disclosed in the document furnished to security holders.
See Instruction
       6 to Item 10 of Schedule TO, Instruction 1 to Item 13 of Schedule 13E-3
and telephone
       interpretation I.H.7 in the July 2001 supplement to our    Manual of
Publicly Available
       Telephone Interpretations    that is available on the Commission   s
website at
       https://www.sec.gov. While we note that you have provided the book value
per share as of
       June 30, 2024, and December 31, 2023, on page 24 of the Offer Letter,
please revise the
       disclosure to include the remaining information required by Item 1010(c)
of Regulation
       M-A and disseminate the amended disclosure as required by Exchange Act
Rule 13e-
       4(e)(3).
2.     It appears that you have not provided the pro forma information called
for by Item
       1010(b) of Regulation M-A. Please include in your response letter an
explanation as to
 August 20, 2024
Page 2

       why the Company believes that pro forma information is not material to a
warrant holder's
       investment decision whether to tender warrants in the Offer.
Alternatively, include such
       information in a revised filing.
3.     In the press release attached as Exhibit (a)(5), we note your last
paragraph regarding
       "forward-looking statements" and reference to "the 'safe harbor'
provisions of the United
       States Private Securities Litigation Reform Act of 1995." The safe
harbor provisions of
       the Private Securities Litigation Reform Act of 1995 are not available
to statements made
       in connection with a going private transaction. See Question 117.05 of
the Division of
       Corporation Finance   s Compliance and Disclosure Interpretations for
Going Private
       Transactions, Exchange Act Rule 13e-3 and Schedule 13E-3, dated January
26, 2009.
       Please refrain from referring to such safe harbor provisions in any
future filings,
       press releases or other communications relating to this going private
transaction.
Fairness of the Transaction (Offer, Consent Solicitation and Redemption), page
6

4.     Item 8 of Schedule 13E-3 and Item 1014(a) of Regulation M-A require the
Company to
       state whether it believes that the Rule 13e-3 transaction is fair or
unfair to "unaffiliated
       security holders," as defined in Exchange Act Rule 13e-3(a)(4). We note
your disclosure
       on page 6 and elsewhere in the Offer to Purchase that Board determined
that the
       Transaction is fair to "holders of Warrants." Please revise to
articulate whether the Board
       believes that the Transaction is fair to unaffiliated warrant holders.
5.     The factors listed in Instruction 2 to Item 1014 of Regulation M-A are
generally relevant
       to a filing person   s fairness determination and should be discussed in
reasonable detail.
       See Question Nos. 20 and 21 of Exchange Act Release No. 34-17719 (April
13, 1981).
       Please revise this section to include the factor in clause (iii) of
Instruction 2 to Item 1014
       or explain why such factor was not deemed material or relevant to the
board's fairness
       determination. If the procedural safeguards in Item 1014(c), (d) and (e)
were not
       considered, please explain why the board of directors believes that the
Rule 13e-3
       transaction is fair in the absence of such safeguards.
6.     In the second and third bullet points under subsection "Factors
Considered" on page 6, we
       note your use of "the last reported sale price of the Warrants on Nasdaq
of $0.40 on
       August 9, 2024, the business day before the Offer was launched" as the
benchmark to
       calculate the "premium" rate. Under subsection "Fairness for Holders Who
Tender or
       Who Do Not Tender," however, you state that consideration received by
both "Warrant
       holders who tender their Warrants in the Offer" and "Warrant holders who
do not tender
       their Warrants in the Offer" is "a premium to the market price on the
day of launch of the
       Offer ($0.40 per Warrant)" (emphasis added). Please confirm in your
response letter
       whether "the market price on the day of launch of the Offer" per Warrant
was also
       $0.40, which, according to your disclosure, was the "last reported sale
price" on "the
       business day before the Offer was launched" (emphasis added), or revise.
7.     Refer to the last paragraph under subsection "Fairness for Holders Who
Tender or Who
       Do Not Tender." Expand this paragraph to provide a more detailed
discussion of "the
       costs and risks" considered by the board of directors.
Board Presentation, page 8

8.     Disclosure on page 9 indicates that    Citigroup and its affiliates
provide banking and
 August 20, 2024
Page 3

       payment services for the Company. The Company has also agreed to
reimburse the cost of
       Citigroup   s legal counsel in an amount up to $150,000.    Please
revise this section to
       quantify any compensation received in the past two years, or to be
received, by Citigroup
       and its affiliates as a result of its relationship with the Company or
its affiliates. Refer to
       Item 9 of Schedule 13E-3, Item 1015(b)(4) of Regulation M-A and Going
Private
       Transactions, Exchange Act Rule 13e-3 and Schedule 13E-3 Compliance and
Disclosure
       Interpretation 217.01.
9.     Disclosure in the last paragraph on page 9 indicates that in addition to
the Presentation,
       Citigroup prepared 2 presentations, constituting the Discussion
Materials, which were
       prepared in contemplation of a share exchange transaction which
management ultimately
       chose not to pursue but shared with the Company   s management.
Disclosure on page 7
       indicates that    [i]n evaluating the Transaction, the Company
considered conducting an
       exchange offer for the Warrants as an alternative in which the Warrants
would be
       exchanged for shares of Common Stock.    Each presentation, discussion,
or report held
       with or presented by Citigroup that is materially related to the Rule
13e-3 transaction,
       whether oral or written, is a separate report that requires a reasonably
detailed description
       meeting the requirements of Item 1015 of Regulation M-A. This
requirement applies to
       both preliminary and final reports. Revise to summarize the Discussion
Materials, and file
       any written materials as exhibits to the Schedule 13E-3 pursuant to Item
9 of Schedule
       13E-3 and Item 1016(c) of Regulation M-A. Refer to Meyers Parking, Rel.
34-26069
       (Sep. 12, 1980) and Charles Ephraim (Sep. 30, 1987).
Effects of the Transaction on the Market for the Warrants, page 9

10.    While your disclosure on page 9 describes "[t]he primary benefits and
detriments to the
       Company, participating Warrant holders and non-participating Warrant
holders," Item
       1013(d) of Regulation M-A requires a reasonably detailed discussion of
the benefits and
       detriments of the transaction to not only the Company but also to its
affiliates and
       unaffiliated security holders. In addition, the benefits and detriments
must be quantified to
       the extent practicable. See Instruction 2 to Item 1013 of Regulation
M-A. Please revise.
11.    On page 10, in describing the benefits "[t]o Warrant holders that
participate in the Offer,"
       you note that "[p]articipating Warrant holders will receive a higher
price if they tender
       their Warrants in the Offer rather than selling their Warrants in the
open market at the
       current market price" (emphasis added). Please revise to define "the
current market
       price," provide a specific benchmark date, or advise.
Interests of Directors and Executive Officers, page 11

12.    On page 13, under footnote (2), we note Mr. Goldman   s disclaimer of
beneficial
       ownership    except to the extent of his pecuniary interest therein.
Similar disclosure
       appears in footnote (3). Please note that beneficial ownership is not
determined based on
       pecuniary interest. See Rule 13d-3(a). Please revise.
Acceptance of Warrants and Payment of Offer Purchase Price, page 22

13.    We note the following sentence on page 23: "In addition, if certain
events occur, we may
       not be obligated to purchase Warrants in the Offer." Please revise to
provide additional
       details, including what "certain events" consist of, or advise.
 August 20, 2024
Page 4

Additional Information; Miscellaneous, page 30

14.     On page 31, you state that warrant holders "can obtain any of the
documents incorporated
        by reference in this Offer Letter from the SEC   s website at the
address described above."
        The address of "the SEC's website," however, does not appear in your
filing except in
        Exhibit (a)(5). Please revise.
        We remind you that the filing persons are responsible for the accuracy
and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

        Please direct any questions to Eddie Kim at 202-679-6943 or Perry
Hindin at 202-551-
3444.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Mergers &
Acquisitions
</TEXT>
</DOCUMENT>
